Insights
Insights From Our Experts
Articles
Alternative Product Distribution Model: Where Agility Meets Profitability
Distributing innovative, life-altering therapies to patients is no small feat, and manufacturers shouldn’t settle for the status quo of an outdated, one-size-fits-all model. As you develop your channel strategy, consider how your distribution model can benefit…
A Time for Transition in Pharma: January 2021
So far, 2021 is proving to be a time for international transition in pharma. In the latest Pricentric INSIGHTS newsletter, we’re taking a closer look at new legislation and regulatory actions happening around the globe to…
Drug Pricing And Drug Price Reporting Regulatory Update
As the new president and Congress begin their terms, EVERSANA would like to provide an update on recent legislative and regulatory actions that affect drug pricing and price reporting. The Centers for Medicare and Medicaid Services…
Upcoming PharmaVOICE Panel – Next Gen Patient Services Models
With increasingly less face-to-face patient interaction, manufacturers need to rethink traditional solutions in order to alleviate access barriers. Despite best efforts, prescription rates continue to drop as newly launched products experience increased patient drop-off; and companies…
Key Factors to Obtaining Reimbursement for Digital Therapeutics in the U.S.
Posted on February 4, 20212/4/21
While wellness apps have been successful in a direct-to-consumer model, many digital therapeutics (DTx) providers are working to obtain reimbursement from U.S. payers. In a heterogenous payer ecosystem, the key question is how to obtain broad…
A Paul Simms Favorite: EVERSANA makes the list for 2021 Predictions
“Imagine there was a third way … an equivalent to the Apple App Store in our industry … maybe that model could start working in pharma; and, in fact, it is.” For pharmaceutical influencer Paul Simms,…
Leveraging Innovative Technology to Improve the Patient Journey
Commercial teams cannot afford to misinterpret the patient and product journeys. Over 50% of new launches fail to meet market forecasts. In addition, newly launched products are experiencing increased patient drop-off due to many U.S. market…
Under the Biden Team & Beyond COVID … What Lies Ahead for Healthcare
Posted by
Dr. Richard Stefanacci on January 29, 20211/29/21
While the obvious healthcare focus for the new Biden/Harris Administration will be on controlling the COVID-19 pandemic, it’s a critical time to assess what lies beyond COVID for their attention. To gain a sense of what’s…
Transforming Commercialization With Industry-Leading Partnerships
Healthcare innovation is being intensified as the industry rushes to find solutions to the pandemic, while furthering research in rare and complex diseases. As pharma companies reignite clinical development, streamlining commercialization is crucial in bridging the…
The 10-Year Test: Is It Possible to Plan Launch During Clinical Development?
Time and strategy are keys to launching in an overwhelmed, unpredictable market. Pharmaceutical companies in mid-development of a drug need to look ahead at their launch strategy options and consider what market conditions could look like by the time they’re ready to commercialize their product. By evaluating the value…